6.
Behnan J, Isakson P, Joel M, Cilio C, Langmoen I, Vik-Mo E
. Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor progression. Stem Cells. 2013; 32(5):1110-23.
DOI: 10.1002/stem.1614.
View
7.
Ajith A, Mamouni K, Horuzsko D, Musa A, Dzutsev A, Fang J
. Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance. J Clin Invest. 2023; 133(21).
PMC: 10617775.
DOI: 10.1172/JCI167951.
View
8.
Filippova N, Grimes J, Leavenworth J, Namkoong D, Yang X, King P
. Targeting the TREM1-positive myeloid microenvironment in glioblastoma. Neurooncol Adv. 2022; 4(1):vdac149.
PMC: 9555298.
DOI: 10.1093/noajnl/vdac149.
View
9.
Wu Q, Berglund A, Etame A
. The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma. Int J Mol Sci. 2021; 22(15).
PMC: 8347012.
DOI: 10.3390/ijms22158324.
View
10.
Lemke D, Weiler M, Blaes J, Wiestler B, Jestaedt L, Klein A
. Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?. J Neurochem. 2014; 131(2):251-64.
DOI: 10.1111/jnc.12802.
View
11.
Kirchhof M, Chau L, Lemke C, Vardhana S, Darlington P, Marquez M
. Modulation of T cell activation by stomatin-like protein 2. J Immunol. 2008; 181(3):1927-36.
PMC: 2913160.
DOI: 10.4049/jimmunol.181.3.1927.
View
12.
Senner V, Ratzinger S, Mertsch S, Grassel S, Paulus W
. Collagen XVI expression is upregulated in glioblastomas and promotes tumor cell adhesion. FEBS Lett. 2008; 582(23-24):3293-300.
DOI: 10.1016/j.febslet.2008.09.017.
View
13.
Chen H, Nikolic A, Singhal D, Gallo M
. Roles of Chromatin Remodelling and Molecular Heterogeneity in Therapy Resistance in Glioblastoma. Cancers (Basel). 2022; 14(19).
PMC: 9563350.
DOI: 10.3390/cancers14194942.
View
14.
Jubelin C, Munoz-Garcia J, Cochonneau D, Ollivier E, Vallette F, Heymann M
. Technical report: liquid overlay technique allows the generation of homogeneous osteosarcoma, glioblastoma, lung and prostate adenocarcinoma spheroids that can be used for drug cytotoxicity measurements. Front Bioeng Biotechnol. 2023; 11:1260049.
PMC: 10588472.
DOI: 10.3389/fbioe.2023.1260049.
View
15.
Drongitis D, Verrillo L, De Marinis P, Orabona P, Caiola A, Turitto G
. The Chromatin-Oxygen Sensor Gene Associates with Novel Hypoxia-Related Signatures in Glioblastoma Multiforme. Int J Mol Sci. 2022; 23(18).
PMC: 9498997.
DOI: 10.3390/ijms231810250.
View
16.
Zhang L, Qu X, Xu Y
. Molecular and immunological features of TREM1 and its emergence as a prognostic indicator in glioma. Front Immunol. 2024; 15:1324010.
PMC: 10869492.
DOI: 10.3389/fimmu.2024.1324010.
View
17.
Oizel K, Chauvin C, Oliver L, Gratas C, Geraldo F, Jarry U
. Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity. Clin Cancer Res. 2017; 23(20):6292-6304.
DOI: 10.1158/1078-0432.CCR-16-3102.
View
18.
Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M
. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110.
PMC: 2818769.
DOI: 10.1016/j.ccr.2009.12.020.
View
19.
Clavreul A, Menei P
. Mesenchymal Stromal-Like Cells in the Glioma Microenvironment: What Are These Cells?. Cancers (Basel). 2020; 12(9).
PMC: 7565954.
DOI: 10.3390/cancers12092628.
View
20.
Shahar T, Rozovski U, Hess K, Hossain A, Gumin J, Gao F
. Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro Oncol. 2017; 19(5):660-668.
PMC: 5464439.
DOI: 10.1093/neuonc/now239.
View